Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors
The delta opioid receptor is a Gi-protein-coupled receptor (GPCR) with a broad expression pattern both in the central nervous system and the body. The receptor has been investigated as a potential target for a multitude of significant diseases including migraine, alcohol use disorder, ischemia, and...
Main Authors: | Yazan J. Meqbil, Richard M. van Rijn |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/7/873 |
Similar Items
-
ClickArr: a novel, high-throughput assay for evaluating β-arrestin isoform recruitment
by: Alexander R. French, et al.
Published: (2023-11-01) -
Molecular Perspectives for mu/delta Opioid Receptor Heteromers as Distinct, Functional Receptors
by: Edmund W. Ong, et al.
Published: (2014-03-01) -
Targeting cryptic allosteric sites of G protein-coupled receptors as a novel strategy for biased drug discovery
by: Xin Qiao, et al.
Published: (2025-02-01) -
Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands
by: Chiara Sturaro, et al.
Published: (2022-04-01) -
The Role of ICL1 and H8 in Class B1 GPCRs; Implications for Receptor Activation
by: Ian Winfield, et al.
Published: (2022-01-01)